Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Status:
Completed
Trial end date:
2008-01-23
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the safety and effectiveness of
pegfilgrastim in reducing grade 3/4 neutropenia when given after one of three chemotherapy
regimens (FOIL, FOLFOX or FOLFIRI) in patients with locally advanced or metastatic colorectal
cancer. This study is considered to be "investigational" because the time between receiving
pegfilgrastim and the next cycle of chemotherapy is only 11 days.